This HTML5 document contains 38 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n11http://linked.opendata.cz/resource/drugbank/drug/DB04173/identifier/drugbank/
n15http://bio2rdf.org/drugbank:
n14http://linked.opendata.cz/resource/drugbank/drug/DB04173/identifier/chebi/
admshttp://www.w3.org/ns/adms#
n8http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n6http://linked.opendata.cz/resource/drugbank/drug/DB04173/identifier/pharmgkb/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n12http://linked.opendata.cz/resource/drugbank/drug/DB04173/identifier/pdb/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n9http://linked.opendata.cz/resource/drugbank/drug/DB04173/identifier/pubchem-compound/
n10http://linked.opendata.cz/resource/drugbank/drug/DB04173/identifier/pubchem-substance/

Statements

Subject Item
n2:DB04173
rdf:type
n3:Drug
n3:group
experimental
owl:sameAs
n8:DB04173 n15:DB04173
dcterms:title
Fructose
adms:identifier
n6:PA449716 n9:439553 n10:46504785 n11:DB04173 n12:FRU n14:28757
n3:synthesisReference
Larry W. Peckous, "Integrated process for producing crystalline fructose and a high-fructose, liquid phase sweetener." U.S. Patent US5656094, issued 0000.
n3:IUPAC-Name
n4:271B413F-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B4145-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B4144-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B4141-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B4142-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B4143-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B413D-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B413B-363D-11E5-9242-09173F13E4C5 n4:271B413E-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B413C-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Acceptor-Count
n4:271B414B-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B414C-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B4146-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B4147-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B4149-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B4148-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B414A-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n4:271B4151-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B4153-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B4154-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B4150-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B414F-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B4152-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B4140-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B414D-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B414E-363D-11E5-9242-09173F13E4C5